Protalix grants director 17K options, 8.5K RSUs

A Protalix BioTherapeutics director received new stock options and RSU awards as part of equity compensation, vesting over 12 quarterly installments.

Available on EDGAR 09/04/2026 - 06:04 AM EDT Accepted by SEC EDGAR 09/04/2026 - 06:00 AM EDT Learn about SEC filing dates

Rhea-AI Filing Summary

Protalix BioTherapeutics, Inc. (PLX) reported that director Amos Bar-Shalev received equity-based compensation on September 3, 2026. He was granted stock options for 17,000 shares of common stock at an exercise price of $2.59 per share, expiring September 3, 2036, and 8,500 restricted stock units. Both the options and RSUs vest in 12 equal quarterly installments starting on the grant date, and no Rule 10b5-1 trading plan is reported.

Insider Trade Summary

Grant/Award: 25,500 shares

Grant/Award 2 txns

Insider Bar-Shalev Amos

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options (Right to Buy) F1, F2	17,000	$0.00	$0.00
Grant/Award	Restricted Stock Units F3, F4	8,500	$0.00	$0.00

Holdings After Transaction: Stock Options (Right to Buy) — 17,000 contracts (Direct); Restricted Stock Units — 8,500 contracts (Direct)

Holdings Before and After: Stock Options (Right to Buy), 0 to 17,000 contracts (Direct); Restricted Stock Units, 0 to 8,500 contracts (Direct)

Footnotes (4)

1. F1. The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant.
2. F2. Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030, (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032, (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 29, 2033, and (iv) options to purchase 15,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035.
3. F3. Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock.
4. F4. The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant.

Key Figures

Stock options granted: 17,000 options Option exercise price: $2.59 per share Option expiration: September 3, 2036 +2 more

5 metrics

Stock options granted 17,000 options Grant to director on September 3, 2026

Option exercise price $2.59 per share Exercise price for 17,000 stock options granted September 3, 2026

Option expiration September 3, 2036 Expiration date of the 17,000 stock options

Restricted stock units granted 8,500 RSUs Grant to director on September 3, 2026

Vesting installments 12 quarterly installments Vesting schedule for both options and RSUs beginning on grant date

Key Terms

Stock Options, Restricted Stock Units, exercise price, vest

4 terms

Stock Options financial

"The shares of common stock underlying the stock options vest in 12 equal quarterly"

Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.

Restricted Stock Units financial

"Each restricted stock unit (RSU) represents the right to receive, following vesting,"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

exercise price financial

"options to purchase 40,000 shares of common stock at an exercise price equal"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest financial

"The shares of common stock underlying the RSUs vest in 12 equal quarterly installments"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What equity awards did PLX grant to director Amos Bar-Shalev?

On September 3, 2026, Amos Bar-Shalev received 17,000 stock options with a $2.59 exercise price per share, expiring September 3, 2036, and 8,500 restricted stock units of Protalix BioTherapeutics common stock as equity compensation.

How do the new stock options for PLX’s director vest?

The stock options for 17,000 shares of Protalix BioTherapeutics common stock vest in 12 equal quarterly installments commencing on the September 3, 2026 grant date, spreading vesting over approximately three years.

What are the terms of the PLX restricted stock units granted on September 3, 2026?

The director received 8,500 restricted stock units, each representing the right to receive, after vesting, one share of Protalix BioTherapeutics common stock. These RSUs vest in 12 equal quarterly installments beginning on the grant date.

What is the exercise price and expiration date of the new PLX stock options?

The newly granted stock options to the director cover 17,000 shares of Protalix BioTherapeutics common stock at an exercise price of $2.59 per share and have an expiration date of September 3, 2036.

Were the PLX director’s September 3, 2026 equity grants under a Rule 10b5-1 plan?

No. The filing’s Rule 10b5-1 checkbox is marked in a way indicating no Rule 10b5-1 trading plan is reported for the September 3, 2026 equity grants to the director.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bar-Shalev Amos

(Last) (First) (Middle)

C/O PROTALIX BIOTHERAPEUTICS, INC.

2 SNUNIT STREET SCIENCE PARK, POB 455

(Street)

CARMIEL 2161401

(City) (State) (Zip)

ISRAEL

(Country)

2. Issuer Name and Ticker or Trading Symbol
Protalix BioTherapeutics, Inc. [ PLX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options (Right to Buy)	$2.59	09/03/2026		A		17,000		(1)	09/03/2036	Common Stock	17,000	$0	17,000(2)	D
Restricted Stock Units	(3)	09/03/2026		A		8,500		(4)	(4)	Common Stock	8,500	$0	8,500	D

Explanation of Responses:

1. The shares of common stock underlying the stock options vest in 12 equal quarterly installments commencing upon the date of grant.

2. Does not include (i) options to purchase 40,000 shares of common stock at an exercise price equal to $3.55 per share that expire on January 20, 2030, (ii) options to purchase 50,000 shares of common stock at an exercise price equal to $1.03 per share that expire on September 7, 2032, (iii) options to purchase 61,676 shares of common stock at an exercise price equal to $1.66 per share that expire on September 29, 2033, and (iv) options to purchase 15,000 shares of common stock at an exercise price equal to $1.64 per share that expire on September 3, 2035.

3. Each restricted stock unit (RSU) represents the right to receive, following vesting, one share of the Isuer's common stock.

4. The shares of common stock underlying the RSUs vest in 12 equal quarterly installments commencing upon the date of grant.

	/s/ Joseph R. Magnas, Attorney-in-Fact	09/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)